Opexa Therapeutics, Inc. 4
4 · Opexa Therapeutics, Inc. · Filed Dec 18, 2013
Insider Transaction Report
Form 4
Radhakrishnan Karthik
Chief Financial Officer
Transactions
- Purchase
Common Stock
2013-12-18$1.70/sh+8,000$13,600→ 58,000 total
Footnotes (1)
- [F1]Purchased in an underwritten public offering which is expected to close on December 23, 2013.